These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33177621)

  • 41. Author Correction: Genomic Prediction of 16 Complex Disease Risks Including Heart Attack, Diabetes, Breast and Prostate Cancer.
    Lello L; Raben TG; Yong SY; Tellier LCAM; Hsu SDH
    Sci Rep; 2019 Nov; 9(1):17515. PubMed ID: 31748697
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Author Correction: Novel 2-phenyloxypyrimidine derivative induces apoptosis and autophagy via inhibiting PI3K pathway and activating MAPK/ERK signaling in hepatocellular carcinoma cells.
    Wang J; Sun P; Chen Y; Yao H; Wang S
    Sci Rep; 2019 Dec; 9(1):19820. PubMed ID: 31852990
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Author Correction: LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer.
    Li Q; Liu B; Chao HP; Ji Y; Lu Y; Mehmood R; Jeter C; Chen T; Moore JR; Li W; Liu C; Rycaj K; Tracz A; Kirk J; Calhoun-Davis T; Xiong J; Deng Q; Huang J; Foster BA; Gokhale A; Chen X; Tang DG
    Nat Commun; 2020 Jun; 11(1):2895. PubMed ID: 32499578
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Author Correction: Flotillin-2 promotes metastasis of nasopharyngeal carcinoma by activating NF-κB and PI3K/Akt3 signaling pathways.
    Liu J; Huang W; Ren C; Wen Q; Liu W; Yang X; Wang L; Zhu B; Zeng L; Feng X; Zhang C; Chen H; Jia W; Zhang L; Xia X; Chen Y
    Sci Rep; 2020 Apr; 10(1):6914. PubMed ID: 32313260
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Author Correction: An exome-wide rare variant analysis of Korean men identifies three novel genes predisposing to prostate cancer.
    Oh JJ; Shivakumar M; Miller J; Verma S; Lee H; Hong SK; Lee SE; Lee Y; Lee SJ; Sung J; Kim D; Byun SS
    Sci Rep; 2020 Feb; 10(1):2481. PubMed ID: 32034279
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.
    Seront E; Rottey S; Filleul B; Glorieux P; Goeminne JC; Verschaeve V; Vandenbulcke JM; Sautois B; Boegner P; Gillain A; van Maanen A; Machiels JP
    BJU Int; 2016 Sep; 118(3):408-15. PubMed ID: 26779597
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell.
    Zhu H; Shi Y; Jiao X; Yang G; Wang R; Yuan Y
    Oncol Lett; 2020 Dec; 20(6):326. PubMed ID: 33123242
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Author Correction: Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors.
    Smolarczyk R; Cichoń T; Pilny E; Jarosz-Biej M; Poczkaj A; Kułach N; Szala S
    Sci Rep; 2020 Mar; 10(1):5698. PubMed ID: 32210342
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
    Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Author Correction: Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces Aβ and P25 accumulation in 5XFAD mice.
    Binyamin O; Nitzan K; Frid K; Ungar Y; Rosenmann H; Gabizon R
    Sci Rep; 2020 Jan; 10(1):1320. PubMed ID: 31974392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
    Zhu G; Foletti D; Liu X; Ding S; Melton Witt J; Hasa-Moreno A; Rickert M; Holz C; Aschenbrenner L; Yang AH; Kraynov E; Evering W; Obert L; Lee C; Sai T; Mistry T; Lindquist KC; Van Blarcom T; Strop P; Chaparro-Riggers J; Liu SH
    Sci Rep; 2019 Nov; 9(1):16735. PubMed ID: 31700121
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research.
    Omar MI; Roobol MJ; Ribal MJ; Abbott T; Agapow PM; Araujo S; Asiimwe A; Auffray C; Balaur I; Beyer K; Bernini C; Bjartell A; Briganti A; Butler-Ransohoff JE; Campi R; Cavelaars M; De Meulder B; Devecseri Z; Voss MD; Dimitropoulos K; Evans-Axelsson S; Franks B; Fullwood L; Horgan D; Smith EJ; Kiran A; Kivinummi K; Lambrecht M; Lancet D; Lindgren P; MacLennan S; MacLennan S; Nogueira MM; Moen F; Moinat M; Papineni K; Reich C; Reiche K; Rogiers S; Sartini C; van Bochove K; van Diggelen F; Van Hemelrijck M; Van Poppel H; Zong J; N'Dow J;
    Nat Rev Urol; 2020 Aug; 17(8):482. PubMed ID: 32587405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Author Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.
    Xu J; Liu Y; Li Y; Wang H; Stewart S; Van der Jeught K; Agarwal P; Zhang Y; Liu S; Zhao G; Wan J; Lu X; He X
    Nat Nanotechnol; 2020 Apr; 15(4):342. PubMed ID: 31953520
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity.
    Liang M; Lv J; Chu H; Wang J; Chen X; Zhu X; Xue Y; Guan M; Zou H
    J Dermatol Sci; 2014 Nov; 76(2):104-11. PubMed ID: 25258031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
    Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S; Flentje M; Djuzenova CS
    Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
    Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS
    Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus.
    Brannon AR; Frizziero M; Chen D; Hummel J; Gallo J; Riester M; Patel P; Cheung W; Morrissey M; Carbone C; Cottini S; Tortora G; Melisi D
    Cold Spring Harb Mol Case Stud; 2016 Mar; 2(2):a000620. PubMed ID: 27148582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.